1433280-60-4

Upstream product

• 457097-93-7 4-amino-3-trifluoromethoxybenzoic acid methyl ester 
• 175278-22-5 4-amino-3-(trifluoromethoxy)benzoic acid 

Downstream Products

• 1433280-63-7 (R)-tert-butyl 4-(5-(4-bromo-3-chloro-5-(trifluoromethoxy)benzamido)pyridin-2-yl)-3-methylpiperazine-1-carboxylate 
• 1433281-30-1 (2S,4S)-tert-butyl 2-(4 (2'-chloro-4'-((6-((R)-2-methyl-4-pivaloylpiperazin-1-yl)pyridin-3-yl)carbamoyl)-6'-(trifluoomethoxy)-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)-4-methylpyrrolidine-1-carboxylate 
• 1433280-62-6 (R)-4-bromo-3-chloro-N-(6-(2-methyl-4-pivaloylpiperazin-1-yl)pyridin-3-yl)-5-(trifluoromethoxy)benzamide 
• 1433280-61-5 4-bromo-3-chloro-5-trifluoromethoxy-benzoic acidmethyl ester 
• 1433280-59-1 4-bromo-3-chloro-5-(trifluoromethoxy)benzoic acid 

Relevant academic research and scientific papers

CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR

Disclosed are compounds of Formula I or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

Btk INHIBITORS WITH IMPROVED DUAL SELECTIVITY

Disclosed herein is a tri-substituted phenyl Btk inhibitors with improved dual selectivity, a method and a composition for inhibiting Btk and treating disease associated with undesirable Btk activity (Btk-related diseases).

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.